Posted by Lamdage22 on September 6, 2014, at 8:37:38
In reply to Re: Can Glyx-13 be utilized in schizophrenia?, posted by Lamdage22 on September 6, 2014, at 8:28:43
"About Glycine-Site Functional Partial Agonists
GFPAs modulate the NMDA receptor in a novel and selective way that results in the largest therapeutic index of any known NMDAR modulator. GFPAs are being developed with the goal of achieving the antidepressant efficacy and rapid onset seen with conventional NMDAR modulators, but without their limiting side effects. The efficacy potential of GFPAs has been demonstrated in animal models in a number of CNS diseases, including major depressive disorder, neuropathic pain, schizophrenia, anxiety, Alzheimer's disease and other cognition disorders. In these studies, GFPAs did not exhibit the schizophrenia-like side effects associated with conventional NMDAR modulating drugs. In preclinical studies, Naurex's lead drug candidate, GLYX-13, has demonstrated a wide therapeutic ratio between efficacy and side effects (>/=500:1). Preclinical studies also have shown that the antidepressant effects of GLYX-13 were evident within 20 minutes and lasted at least two weeks after administration of a single dose."
So they have done animal studies! In those, even schizophrenic mice have not reacted with psychosis to Glyx-13/NRX1074
I can't find where a doctor said, that they are planning to study it on Schizophrenic patients.Schizophrenia and Depression
Seroquel 800mg
Zyprexa 5mg
Lithium orotate 480mg
Metformin 1500mg
Effexor 20mg
poster:Lamdage22
thread:1069315
URL: http://www.dr-bob.org/babble/20140815/msgs/1070847.html